Treatment of schizophrenia: This product is effective for positive symptoms of schizophrenia and also has a certain effect on negative symptoms. It can also alleviate the emotional symptoms associated with schizophrenia, such as depression, anxiety and cognitive deficits.
Treatment of depressive episodes in bipolar affective disorder: This product can rapidly control depressive symptoms in bipolar affective disorder. It is effective for both bipolar I and II patients.
This product is indicated for the prevention of atherothrombosis events in:
1. Patients with recent myocardial infarction, recent ischemic stroke or confirmed peripheral arterial disease.
2. Patients with acute coronary syndrome.
3. Patients with non-ST-segment elevation acute coronary syndrome (including unstable angina or non-Q wave myocardial infarction), including patients with stent placement following percutaneous coronary intervention.
4. Patients with ST-segment elevation acute coronary syndrome.
This product is indicated for the treatment of acute or chronic schizophrenia dominated by positive symptoms (delirium, hallucination, cognitive impairment, etc.) and/or negative symptoms (psychomotor retardation, apathy, social withdrawal, etc.). It is also effective for schizophrenia characterized by negative symptoms.
This product is indicated for the treatment of schizophrenia. Olanzapine can maintain its basic clinical efficacy during maintenance treatment in patients responsive to the initial treatment. It is also indicated for the treatment of moderate to severe manic episodes and the prevention of relapse in bipolar affective disorder.